admin – Page 7331 – Get News Story

Ahmed Alshuwaikhat’s ‘The American Translator’: A Symphony of Diversity and Unity

Step into a world where cultures collide, mysteries unravel, and the heartbeat of humanity echoes louder than the roar of war. Prepare to embark on an odyssey that transcends borders and challenges perceptions.

Introducing “The American Translator: From San Francisco To Battlefields In Iraq” – an electrifying fusion of intercultural exploration and heart-stopping suspense. Brace for a literary journey that defies conventions and leaves an indelible mark on the soul.

At its core, this gripping narrative follows the enigmatic David Boccaccio, a wanderer drawn by the siren call of art and the allure of translation. From the vibrant streets of San Francisco to the unforgiving sands of Iraq, join David as he navigates a labyrinth of danger and discovery, his fate hanging in the balance with each twist of the plot.

But “The American Translator” is more than just a tale of survival; it’s a testament to the resilience of the human spirit in the face of adversity. As David confronts the shadows of war and the complexities of his own existence, readers are swept into a whirlwind of emotion and enlightenment.

Spanning continents and cultures, this literary masterpiece transcends boundaries, weaving a rich tapestry of music, art, and literature from around the globe. From the bustling cities of Europe to the tranquil landscapes and arts of the Middle East, China, India, Russia and others, every page is a symphony of diversity and unity.

As the world teeters on the brink of chaos, “The American Translator” stands as a beacon of hope and understanding. Join an unforgettable journey and discover the true meaning of courage, compassion, and connection.

Don’t miss the chance to experience the novel that will entertain and leave anyone breathless and yearning for more. “The American Translator” – a revelation awaits.

About the Author:

Ahmed Alshuwaikhat, an accomplished author from Saudi Arabia with three novels. The American Translator is his debut in English. The author earned his M.A. in Multicultural Education and English from the University of San Francisco, and his Ph.D. from Stanford University in the field of the Sociology of Language and Education. This has placed him in the academic world as a university teacher. However, after a short academic career, he opted to pursue independent cultural projects, directing the project of The Global Arabic Encyclopedia and working as the Project General Manager for two decades and the Editor-in-Chief of the founding print edition. He has recently devoted his time to writing and traveling. His major literary concerns center on alienation, cultural change, conflict, and intercultural dialogue.

Availability:

“The American Translator: From San Francisco to Battlefields in Iraq” is available for purchase in digital and print formats at Amazon: https://a.co/d/7EBx04i

For contacting the author:

Please send a direct message to Ahmed Alshuwaikhat through his website: https://ahmedmahdialshuwaikhat.com/contact/ Or through the above Media Team Email writingtwicks@gmail.com addressed to the author.

With regards from the Media Team on Behalf of the Author

Media Contact
Contact Person: Ahmed Alshuwaikhat
Email: Send Email
Country: United States
Website: https://ahmedmahdialshuwaikhat.com/

Vagus Nerve Stimulator Market Expected To Grow at a CAGR Of 9.06%, Asserts Delveinsight | Companies – Livanova, Soterix Medical Inc, Microtransponder Inc, Parasym Ltd

“Vagus Nerve Stimulator Market”

Vagus Nerve Stimulators Market By Product Type (Invasive VNS Devices and Non-Invasive VNS Devices), Application (Migraine, Epilepsy, Depression, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography is expected to grow at a steady CAGR (forecast period- 2023-2028) owing to increasing prevalence of neurological disorders and growing popularity of non-invasive VNS devices.

The global vagus nerve stimulators market was valued at USD 426.22 million in 2022, growing at a CAGR of 9.06% during the forecast period from 2023 to 2028 to reach USD 717.17 million by 2028.

The demand for vagus nerve stimulators is witnessing a surge primarily due to the rising prevalence of neurological diseases such as epilepsy, headache disorders such as migraine, and others that have proven to receive benefit from VNS therapy, increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications such as tinnitus and chronic pain besides the approved ones, technological advancements leading to the development of new products such as non-invasive VNS devices thereby boosting the growth of the vagus nerve stimulators market during the forecast period from 2023-2028.

Some of the key market players operating in the Vagus Nerve Stimulator market include LivaNova (NASDAQ: LIVN), Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore (NASDAQ: ECOR), tVNS Technologies GmbH, and others.

DelveInsight’s “Vagus Nerve Stimulator Market Insight & Forecast” report will offer an in-depth understanding of the Vagus Nerve Stimulator market, further benefiting the competitors or stakeholders operating in the Vagus Nerve Stimulator arena.

Vagus Nerve Stimulator Overview

A vagus nerve stimulator is a pacemaker like device which comes with an implantable programmable generator that is implanted in the chest wall and delivers electrical impusles to the vagus nerve in the neck thereby stimulating the vagus nerve and providing relief to patients.

Interested to know more about the functioning of Vagus Nerve Stimulator- Visit @ Vagus Nerve Stimulator Operations & Working.

Vagus Nerve Stimulator Market Insights

Among all the regions, North America is estimated to account for the largest share in the vagus nerve stimulators market. The key driving factors of the North America vagus nerve stimulators market are high prevalence of epilepsy, depression in the region, increasing disposable income, and rising investments and big collaborative expansions by key players in the region. Moreover, the conducive regulatory environment in the region are expected to establish the dominance of North America VNS market in the overall global landscape.

One of the key driving factors of the United States vagus nerve stimulators market is the interplay of various factors in the country. This domination is due to the increase in epileptic population, increasing prevalence of headache disorders such as migraine, and depression in the country. Furthermore, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the country.

For instance, as per the data cited by the National Headache Association (2022), approximately 40 million American are living with migraine and headache disorders in the country. Therefore, the presence of large patient population suffering from migraine and headache disorders correlates to the presence of a potential patient population that may resort to using VNS devices as a treatment method, thus driving the product demand in the nation. Moreover, increasing epileptic population is also expected to drive the demand for vagus nerve stimulators in the country. For instance, as per the data provided by the Centers for Disease Control and Prevention (2020), in 2015, about 3.4 million people across the nation were diagnosed with epilepsy of which 470,000 were children. As mentioned by the International League Against Epilepsy, one-third of epileptic patient population continue to have seizures despite being on anti-seizure medication. This presents another opportunity for VNS devices as they have been reported and approved for medical use for treating drug-resistant epilepsy.

Also, advanced product launches and commercialization agreements among the key companies are further expected to fuel the market. For instance, in August 2021, the US Food and Drug Administration approved drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms the first-of-its kind VNS device- the MicroTransponder Vivistim Paired VNS System. Thus, the interplay of all the aforementioned factors are likely to fuel the market growth of vagus nerve stimulators in the United States during the forecast period

Besides United States, product development activities in Canada also provide supportive growth opportunities for the North America vagus nerve stimulators market. For instance, the Canadian Health regulatory body Health Canada authorized the Dolphin vagus nerve stimulator for emergency use in the treatment of COVID-19 induced acute respiratory distress syndrome.

Thus, all these activities point towards the presence of conducive growth environment in the North American region, ultimately influencing the market growth of this regional market.

To read more about why North America is leading the market growth in the Vagus Nerve Stimulator market, get a snapshot of the Vagus Nerve Stimulator market report.

Vagus Nerve Stimulator Market Dynamics

The vagus nerve stimulators market is experiencing an increase in product demand for a variety of reasons with one of the key reasons being the rising prevalence of neurological disorders. As per the data cited by the World Health Organization (WHO) (2022), over 50 million people across the globe suffer from epilepsy. The source further stated that the estimated proportion of the general population with active epilepsy (i.e. persistent seizures or that require treatment) at any given time is between 4 and 10 per 1000 people. Additionally, in another factsheet by the WHO, it was stated that approximately 264 million people suffer from depression globally. Neurological indications such as epilepsy and depression can be extremely debilitating for patients and are often become refractory to pharmacological treatments. Moreover, pharmacological treatments in such indications are often accompanied with severe side-effects.

Owing to these, an alternative approach such as vagus nerve stimulation has been a preferred mode of treatment in drug-resistant cases of depression, epilepsy as well as it is also being administered in combination with pharmacological treatments in order to provide synergistic effect to patients. Vagus nerve stimulation has been reported to provide positive results in terms of preventing seizures in epileptic patients. Additionally, many studies reported that patients who received vagus nerve stimulation for epilepsy, showed clinical improvement with depression unrelated to the effect of the VNS on their seizures with nearly 40-50% improvement in patients with non-psychotic major depression.

Moreover, with more positive results being reported concerning the VNS therapy, more research is being conducted on different disease areas which may further expand the application of vagus nerve stimulation in coming years. For instance, several studies are ongoing in studying the effects of VNS on tinnitus, irritable bowel syndrome, and chronic pain among other indications. This further presents an opportunity for making significant headway in the VNS market in the near future.

However, procedure-related complications and high cost of these devices may be confining factors for the vagus nerve stimulators market growth.

Along with the factors mentioned above, the vagus nerve stimulators market witnessed a period of slow growth due to the COVID-19 pandemic. The lockdown implemented by various governments worldwide to curb the spread of the COVID-19 infection resulted in suspension of various surgeries and outpatient consultations across all medical specialties including specifically impacting elective procedures. This led to a considerable decrease in the demand for VNS devices as VNS procedures were classified under elective procedures. Furthermore, the implementation of global lockdown in varying degrees further affected the procurement and supply chain. However, the approval of various COVID-19 vaccines and the implementation of mass vaccination programs have paved the way for resumption of vagus nerve stimulators demand, thereby providing a positive growth environment for the vagus nerve stimulators market during the forecast period.

Recent Breakthroughs in Vagus Nerve Stimulator Market:

In August 2021, the US Food and Drug Administration approved the MicroTransponder Vivistim Paired VNS System, a one-of-its-kind, drug rehabilitation system with the intention to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.
In March 2020, LivaNova received the CE Mark approval for their Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™ for difficult-to-treat depression.

Key Players Proactively Working In the Vagus Nerve Stimulator Market

Key Vagus Nerve Stimulator companies involved in manufacturing and production are making significant growth in the advancement of these devices. To boost their market position, they also engage in mergers and acquisitions. Some of the key Vagus Nerve Stimulator companies operating actively in the Vagus Nerve Stimulator market include LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH and others.

Request for Sample Report to know more about: Vagus Nerve Stimulator companies

Scope of the Vagus Nerve Stimulator Market Report:

Geography Covered: Global
Key Vagus Nerve Stimulator Companies: LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH and others.
Market Segmentation by Product Type: Invasive VNS Devices And Non-Invasive VNS Devices
Market Segmentation by Application: Migraine, Epilepsy, Depression, And Others
Market Segmentation By End-User: Hospitals, Specialty Clinics, And Others
Market Segmentation by Geography: North America, Europe, Asia-Pacific, Rest of the World (Middle East, Africa, and South America)
Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents

1. Report Introduction

2. Executive Summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Vagus Nerve Stimulator Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Vagus Nerve Stimulator Market

7. Vagus Nerve Stimulator Market Layout

8. Vagus Nerve Stimulator Global Company Share Analysis – Key 3-5 Companies

9. Vagus Nerve Stimulator Companies and Product Profiles

10. Project Approach

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vagus Nerve Stimulator Market Expected To Grow at a CAGR Of 9.06%, Asserts Delveinsight | Companies – Livanova, Soterix Medical Inc, Microtransponder Inc, Parasym Ltd

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Epidemiology, Therapies, Treatment, Patient Data by DelveInsight | Companies – Biomarin Pharmaceutical, Lysogene, Roche, Biogen, Pfizer

“Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market”

(Albany, US) DelveInsight’s “Adeno-Associated Virus Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Adeno-Associated Virus Vectors in Gene Therapy, historical and forecasted epidemiology as well as the Adeno-Associated Virus Vectors in Gene Therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy report:

According to DelveInsight’s analysis, the market size for AAV vectors in gene therapy across the 7MM is expected to grow with a significant CAGR by 2032.
DelveInsight’s analysis reveals that the prevalent cases of selected indications for AAV gene therapies in the 7MM were reported as ~3 million in 2020.
Leading AAV vectors in gene therapy companies such as MeiraGTx UK II Ltd, Janssen Research & Development, Adverum Biotechnologies, Inc., Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences, Sio Gene Therapies, Takeda (Shire), Bayer, Pfizer, Freeline Therapeutics, Asklepios BioPharmaceutical, UniQure Biopharma B.V., GenSight Biologics, Regenxbio, Sangamo Therapeutics, Lysogene, Sarepta Therapeutics, Esteve, Abeona Therapeutics, Audentes Therapeutics, Ultragenyx Pharmaceutical, Homology Medicines, BioMarin Pharmaceutical, Spark Therapeutics, Astellas Therapeutics, Actus Therapeutics, GenSight Biologics, 4D Molecular Therapeutics, Roche, Coave Therapeutics, Applied Genetic Technologies Corporation, Vivet Therapeutics, and others are developing novel AAV vectors in gene therapy that can be available in the AAV vectors in gene therapy market in the coming years.
The promising AAV vectors in gene therapies in the pipeline include AAV-CNGA3, AAV-CNGB3, AGTC-402 (ACHM CNGA3), ACHM B3 (rAAV2tYF-PR1.7-hCNGB3), ADVM-022 (AAV.7m8-aflibercept), AT-GTX-502 (scAAV9.P546.CLN3), AT-GTX-501 (scAAV9.CB.CLN6), scAAV1.tMCK.NTF3, SPK 7001 (AAV2-hCHM), 4D-110, PF-06939926, Delandistrogene moxeparvovec (SRP-9001), scAAV9.U7.ACCA, SGT-001, 4D-310, Isaralgagene civaparvovec, FLT190, AXO-AAV-GM1, AXO-AAV-GM2, DTX401 (AAV8G6PC), Valoctocogene Roxaparvovec (BMN 270), Giroctocogene fitelparvovec (SB-525 or PF-07055480), RG6357 (SPK-8011), RG6358 (SPK-8016), TAK-754 (BAX 888/SHP654), BAY2599023 (DTX201 AAV FVIII), Fidanacogene elaparvovec (SPK-9001/ PF-06838435), Verbrinacogene setparvovec (FLT-180a), AskBio009 (BAX 335, AAV8.sc-TTR-FIXR338Lopt), AMT-130, LUMEVOQ (GS010; lenadogene nolparvovec), SRP-9004 (MYO 102/ scAAVrh74.tMCK.hSGCA), RGX-121, RGX-111, SB-318, ABO-101 (rAAV9.CMV.hNAGLU), LYS-SAF302 (Olenasufligene Relduparvovec), EGT-101 (AAV9-CAG-coh-SGSH), ABO-102 (scAAV9.U1a.hSGSH), AT132, DTX301 (scAAV8OTC), NLX P101 (AAV-GAD), HMI-102, BMN 307, SPK-3006, AT845, ACTUS-101, GS030, AAV-RPGR, AAV-RPE65, 4D-125, ATGC-501 (rAAV2tYF-GRK1-RPGR), CTx-PDE6b, rAAV-hRS1, VTX-801, and others.

Get more comprehensive insights into how Adeno-Associated Virus (AAV) Vector-Based Gene Therapy epidemiological trends are impacting current and forecasted Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Epidemiology Analysis and Forecast

Key Benefits of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Report:

The report covers the descriptive overview of Adeno-Associated Virus Vectors in Gene Therapy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Adeno-Associated Virus Vectors in Gene Therapy epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Adeno-Associated Virus Vectors in Gene Therapy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Adeno-Associated Virus Vectors in Gene Therapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adeno-Associated Virus Vectors in Gene Therapy market

To know more about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market report offerings, click here @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Insight

The key players in Adeno-Associated Virus Vectors in Gene Therapy market are:

Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical: Phase III
PF-06939926: Pfizer: Phase III
Fidanacogene elaparvovec: Pfizer (initiated by Spark Therapeutics): Phase III
AMT-061: uniQure/CSL Behring: Phase III
Timrepigene emparvovec (BIIB111): NightstaRx Ltd, a Biogen Company: Phase III
Giroctocogene fitelparvovec (SB-525): Pfizer (previously Sangamo Biosciences): Phase III
BIIB112 (AAV8-RPGR): NightstaRx Ltd, a Biogen Company: Phase II/III
NLX P101 (AAV-GAD): MeiraGTx: Phase II
VY-AADC (NBIb-1817/ AAV2-hAADC): Neurocrine Biosciences/ Voyager Therapeutics: Phase II
SPK-8011: Roche (previously Spark Therapeutics)/Pfizer: Phase I/II
ST-920: Sangamo Therapeutics: Phase I/II
FLT190: Freeline Therapeutics: Phase I/II
SPK-3006 (AAV-sec-GAA): Spark Therapeutics: Phase I/II
ACTUS-101: Asklepios Biopharmaceutical (Actus Therapeutics): Phase I/II
AT845: Audentes Therapeutics: Phase I/II
SRP-9001: Roche/Sarepta Therapeutics: Phase I/IIa
HORA-PDE6B: Horama S.A.: Phase I/II
AAV-RPGR (AAV2/5-RPGR): MeiraGTx UK II Ltd: Phase I/II
RGX-121: RegenxBio: Phase I/II
SB-913: Sangamo Therapeutics: Phase I/II
AT-GTX-501 (scAAV9.CB.CLN6): Amicus Therapeutics: Phase I/IIa
AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics: Phase I/IIa

To know in detail about the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy treatment landscape, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies and drugs

Adeno-associated virus (AAV) belongs to the genus Dependoparvovirus within the family Parvoviridae. Its life cycle is dependent on the presence of a helper virus, such as AdV, hence its name and taxonomy classification. AAV is found in multiple vertebrate species, including human and non-human primates (NHPs). The current consensus is that AAV does not cause any human diseases. It is composed of an icosahedral protein capsid of ~26 nm in diameter and a single-stranded DNA genome of ~4.7 kb that can either be the plus (sense) or minus (anti-sense) strand.AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases.

Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field.

Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with few AAV-based therapeutics gaining regulatory approval in Europe and the United States.

Do you want to know how much market share the emerging therapies are going to capture by 2032? Contact: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook

Table of Contents:

1. Key Insights

2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy

3. Competitive Intelligence Analysis for Adeno-Associated Virus Vectors in Gene Therapy

4. Adeno-Associated Virus Vectors in Gene Therapy: Market Overview at a Glance

5. Adeno-Associated Virus Vectors in Gene Therapy: Disease Background and Overview

6. Patient Journey

7. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Unmet Needs

10. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment

11. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Marketed Products

12. Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies

13. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Outlook

16. Access and Reimbursement Overview of Adeno-Associated Virus Vectors in Gene Therapy

17. KOL Views

18. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers

19. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

To know more about Emerging Adeno-Associated Virus (AAV) Vector-Based Gene Therapies, click here: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Treatment Scenario

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Epidemiology, Therapies, Treatment, Patient Data by DelveInsight | Companies – Biomarin Pharmaceutical, Lysogene, Roche, Biogen, Pfizer

Personalized longevity company Qyral launches prescription hair loss products.

Qyral launches personalized hair loss treatments designed to accelerate hair growth and reduce hair loss.

Qyral, a leader in personalized longevity and healthcare solutions, announced their launch into the prescription hair loss space with two new medications: Revive: Oral Rx Hair Regrowth Treatment (oral capsule) and Revive: Topical Rx Hair Regrowth Treatment (topical serum).

At the heart of Qyral’s approach lies its commitment to personalization. Customers begin by completing a detailed hair loss quiz. From there, a team of board-certified dermatologists meticulously reviews the quiz results, prescribing personalized formulas tailored to each individual’s specific needs and goals. Each ingredient in the personalized formulation is science-backed and clinically proven to address hair loss and other hair loss-related concerns. Through a seamless integration of technology and medical expertise, Qyral is empowering its customers to address their hair loss concerns with precision and efficacy.

“We believe that everyone deserves a personalized approach to healthcare, and that includes hair loss treatment,” says Hanieh Sigari, Founder and CEO of Qyral. “With Revive, we wanted to leverage our core competencies of telehealth and personalization to find a way to help individuals take control of their hair health like never before.” As Qyral continues to expand its offerings, Sigari and the Qyral team remain committed to providing unparalleled solutions backed by medical expertise that help individuals age well and live well.

To try Revive: Oral or Revive: Topical, individuals can visit Qyral.com and complete the hair quiz to start the process. After a doctor reviews the information, they may prescribe a formula personalized for the patient, and the prescription will be delivered directly to the patient’s door.

About Qyral

Qyral was founded in 2019 with the mission of helping people age well and live well. Since then, Qyral has grown to a personalized longevity company that offers prescription and non-prescription dermatology and weight management solutions. For more information about Qyral, visit www.Qyral.com.

Media Contact
Company Name: Qyral
Contact Person: Olha Ivasiuk
Email: Send Email
Phone: +1 855-496-0655
Country: United States
Website: https://www.qyral.com/

AirVoel Sets New Standards in Sleep Wellness with Advanced ResMed CPAP and Travel CPAP Solutions

AirVoel, a leading provider of sleep apnea solutions, is transforming the landscape of sleep wellness with its extensive range of ResMed CPAP machines and innovative Travel CPAP devices. Under the visionary leadership of CEO Roman Korytski, AirVoel is committed to enhancing the sleep health of individuals suffering from sleep apnea by offering cutting-edge, accessible, and user-friendly CPAP technology.

In today’s fast-paced world, the importance of a good night’s sleep cannot be overstated, particularly for those battling sleep apnea. AirVoel’s introduction of the latest ResMed CPAP machines and portable Travel CPAP devices is a game-changer for anyone seeking effective and convenient sleep apnea treatment.

“At AirVoel, we are dedicated to breaking down the barriers to achieving optimal sleep health,” stated Roman Korytski, CEO of AirVoel. “By offering top-of-the-line ResMed CPAP machines and our compact Travel CPAP devices, we are empowering individuals to take control of their sleep apnea, both at home and on the go.”

AirVoel simplifies the journey towards better sleep by providing an innovative at-home sleep testing service, allowing individuals to undergo sleep apnea diagnosis in the comfort of their own homes. This service, which includes a comprehensive sleep report and, if necessary, a prescription for CPAP therapy, streamlines the process of obtaining a diagnosis and starting treatment.

Once diagnosed, AirVoel’s clients have access to the latest advancements in CPAP technology, including the renowned ResMed AirSense 10 and AirSense 11 devices, known for their intuitive design, advanced comfort features, and smart connectivity. For those who travel frequently or prefer a more compact solution, AirVoel’s Travel CPAP machines offer the perfect blend of portability and performance, ensuring uninterrupted therapy wherever life takes them.

“Understanding the diverse needs of our clients is at the core of what we do,” added Korytski. “Whether it’s the advanced features of the ResMed CPAP machines or the convenience of our Travel CPAP devices, our goal is to provide personalized solutions that fit seamlessly into each individual’s lifestyle, ensuring they receive the restorative sleep they deserve.”

AirVoel’s commitment to sleep wellness extends beyond providing top-tier CPAP equipment. The company is also dedicated to educating the public about sleep apnea and the critical role of effective treatment in improving overall health and quality of life. With a team of sleep care specialists, AirVoel offers unmatched support and guidance, from the initial diagnosis to ongoing therapy management, ensuring clients feel confident and supported at every step of their treatment journey.

As AirVoel continues to lead the way in CPAP technology and sleep wellness, its unwavering dedication to quality, innovation, and client care is setting new standards in the treatment of sleep apnea. With AirVoel, individuals have a trusted partner in their journey to better sleep and improved health, demonstrating the company’s commitment to making restful nights and energetic days a reality for everyone.

About AirVoel

AirVoel is a premier provider of sleep apnea testing and CPAP solutions, including the latest ResMed CPAP machines and Travel CPAP devices. Based in Toronto, Canada, AirVoel is committed to improving sleep health through innovative products, personalized care, and comprehensive education on sleep wellness.

Media Contact
Company Name: Air Voel
Contact Person: George
Email: Send Email
City: Toronto
State: Ontario
Country: Canada
Website: https://airvoel.ca/

BIGTXN Unveils Innovative Handbook for Navigating Sanctioned Securities

BIGTXN, the UK-headquartered compliance and financial data provider, has unveiled the industry’s first-ever in-depth guide to sanctioned securities and best practices. The handbook, “Navigating Compliance: Guide to Sanctioned Securities,” has been authored by Jeff Teahan, who is a sanctions product specialist at BIGTXN, in collaboration with industry giants Dow Jones Risk & Compliance, Baker McKenzie, and the Association of Certified Sanctions Specialists (ACSS).

The handbook equips compliance professionals across the financial services industry with essential tools for navigating the complex global sanctions landscape. BIGTXN has leveraged its expertise and collaboration with industry leaders, to demystify financial sanctions, empowering practitioners to proactively mitigate risks and ensure compliance. Supported by a survey of compliance professionals and industry insights, the handbook provides immediate practical value for sanctions and compliance practitioners.

“We are thrilled to present the ‘Navigating Compliance’ handbook, a trailblazing initiative that addresses a critical knowledge gap in the financial services industry,” said Haider Mannan, CEO of BIGTXN. “This guide, unparalleled in its scope, is a testament to our commitment to providing cutting-edge resources for compliance professionals.”

Key highlights of the handbook include:

Unprecedented detail: The handbook is the first of its kind, providing financial services professionals with an unparalleled understanding of sanctioned securities and offering practical insights to ensure compliance.
Expert collaboration: Crafted in collaboration with industry leaders Dow Jones Risk & Compliance, Baker McKenzie, and ACSS, the handbook brings together the collective expertise of renowned organizations to deliver a complete picture.
Best practice guide: Backed by real-world case studies and data, the handbook goes beyond theoretical concepts, providing practitioners with actionable insights and a best practice guide to navigate the dynamic sanctions landscape.
Made by experts for experts: Tailored for compliance professionals in investment banks, hedge funds, asset managers, and related sectors, the handbook addresses the specific challenges faced by financial institutions in ensuring regulatory compliance.

As financial institutions grapple with increasing reporting obligations and a lack of clear guidance, “Navigating Compliance: Guide to Sanctioned Securities” emerges as a beacon of clarity and a crucial resource for professionals seeking to stay ahead in the rapidly changing sanctions landscape.

Michael Heller, Head of Financial Crime Proposition, Dow Jones Risk & Compliance said:

“Dow Jones Risk & Compliance exists to help compliance professionals to mitigate the challenges associated with sanctions compliance data, especially in regards to volume and complexity. We are delighted to partner with BIGTXN on this handbook to drive further progress in understanding and addressing these challenges in the context of financial instruments.”

Sven Bates, Counsel for International Trade, Baker McKenzie said:

“As the breadth and complexity of sanctions continues to expand with speed across multiple jurisdictions, there is a growing need for sharing of knowledge and learnings across multiple communities. This handbook provides users with a range of insights into the implementation and application of sanctions in practical contexts to help develop awareness and contribute to industry best practices.”

Anna Sayre, Programs Director, ACSS said:

“We are pleased to support this initiative, which strives to be a practical, easy-to-use resource for sanctions professionals worldwide. It is our hope that the book will serve to drive standards of best practice across the industry and make the important work of the sanctions community that much simpler.”

A copy of the handbook can be downloaded here: https://bit.ly/sanctions-sec-handbook

For further information, please contact:

FAO: Press Office – hello@bigtxn.com

+44 20 8123 9050 / +1 321 766 6777

About BIGTXN

BIGTXN delivers the world’s leading securities data solutions to financial services firms allowing them to stay compliant with sanctions. We employ cutting-edge technologies to seamlessly connect disparate datasets to create the most comprehensive securities data. Investors can now navigate the financial landscape with confidence, gaining a crystal-clear understanding of the products and assets they are investing in. BIGTXN is actively transforming the securities landscape, giving you the power to know like never before.

Media Contact
Company Name: BIGTXN
Email: Send Email
Phone: 02081239050
Country: United Kingdom
Website: https://www.bigtxn.com

Startup Sherpas Unveils Obama Administration Alumni, Natalia Olson-Urtecho, as New Director of Government, Innovation & Growth

In a significant boost to its global initiative, social enterprise, Startup Sherpas, proudly announces the appointment of Natalia Olson-Urtecho as Director of Government, Innovation & Growth.

Startup Sherpas is a forward-thinking organisation committed to empowering the next generation of entrepreneurs through paid work experience opportunities, with offices in both the UK, and Barcelona.

Olson-Urtecho, whose illustrious career includes serving as a Presidential Appointee during Barack Obama’s administration, brings a wealth of experience in fostering innovation, entrepreneurship, and sustainable development on a global scale.

Having served as the Regional Administrator for the U.S. Small Business Administration under President Obama, Natalia Olson-Urtecho oversaw critical initiatives that supported entrepreneurship and small businesses.

Her tenure is notable for managing significant federal contracts and loan programmes, enhancing infrastructure for small business growth across the Mid-Atlantic region. This experience is particularly relevant to Startup Sherpas’ mission to empower young entrepreneurs globally, especially following its recent announcement of the company’s new Barcelona office that has just opened at Tech Barcelona.

“Welcoming Natalia into our team underscores our commitment to drawing on diverse, high-level expertise to enrich our successful programme and extend its reach to more young people worldwide,” said Katherine Walker, Chief Impact Officer at Startup Sherpas.

“Her unique blend of experience in both the public and private sectors will help us tailor our approach to meet the needs of our future young entrepreneurs in different cultural and economic contexts – particularly as we look to Latin America and the Mediterranean.”

Olson-Urtecho’s extensive background in international, regional, and local government operations, digital transformation, and sustainable development makes her an invaluable asset to Startup Sherpas as it expands its startup training platform globally.

Her proven track record of leveraging technology for societal benefit aligns with Startup Sherpas’ vision of creating a generation of innovators ready to tackle global challenges such as climate change, sustainable food systems, and economic stability.Reflecting on her new role, Olson-Urtecho said: “I am excited to join Startup Sherpas and to leverage my experience to empower young people with the entrepreneurial skills they need to make a difference.

“Together, we can build a network of innovative leaders poised to solve the world’s most pressing problems.”

Professor Ger Grauss OBE, a renowned global education consultant and adviser to Startup Sherpas, added: “The addition of Natalia Olson-Urtecho to the Startup Sherpas team is a game-changer.

“Natalia’s expertise and vision will undoubtedly accelerate our efforts to empower young entrepreneurs to tackle the world’s most pressing challenges.”

Mayor Collboni of Barcelona emphasises the local commitment to youth and innovation that made Barcelona such a good match for Startup Sherpas “We know that for every sector of our economy, we need the very best talent to support them. And we know our young people need to see opportunities to work, to create startups and have a vibrant career in Barcelona. Paid work experience while they are still at school and the ability to create their own startups even before they leave school mean they have real experience. They have developed workplace skills and that will meet both these needs.”

Startup Sherpas’ expansion into the Mediterranean and Latin America marks a significant step in its journey to create a global community of one million young entrepreneurs by 2029.

With the support of the British Embassy, the Spanish Government, and now Natalia Olson-Urtecho, the organisation is well-positioned to inspire and nurture the next generation of global innovators.

For media inquiries, partnership opportunities, or more information about Startup Sherpas and its mission, please contact:

press@startupsherpas.co.uk

Hugo Pickford-Wardle

Founder – Startup Sherpas

+44(0)7869412356

Spanish Language Enquiries:

Natalia Olson-Urtecho

Director of Government Innovation & Growth

+34697485492

+12027384363

Natalia@startupsherpas.co.uk

About Startup Sherpas:

Startup Sherpas is a pioneering organisation dedicated to equipping teenagers with startup skills through a unique model that blends paid work experience with junior startup training.

Committed to addressing global challenges through innovation, Startup Sherpas has educated almost 5000 teenagers in the UK, and is now poised to expand its influence internationally. The organisation champions the power of a global generation of innovators to solve the world’s most pressing problems.

About Natalia Olson-Urtecho:

Natalia is a serial entrepreneur, Obama Appointee, Venture Capitalist and triathlete with a deep understanding of global politics and the practicalities of startup life. You can find out more here:

https://www.linkedin.com/in/nataliaolsonurtecho

Media Contact
Company Name: Startup Sherpas
Email: Send Email
Phone: +44(0)7869412356
Country: United Kingdom
Website: https://www.startupsherpas.org

Jon Michail & Image Group International Win International Leadership Award in Dubai

26 February, 2024 – Jon Michail and Image Group International wins Excellence in Finance Leaders Education and Training Award FiNext Awards Dubai 2024.

Image Group International announced today that their Wall Street Gravitas™ coaching program was named the winner of Excellence in Finance Leaders – Education & Training Award.

“It’s a great honour to be recognised for this award and is a testament to our clients trust and success by partnering with us in our authentic personal brand coaching and advisory service.” said Jon Michail, Group CEO of Image Group International

The FiNext Awards is a prestigious recognition program that acknowledges companies in the finance and fintech sector. The aim is to honour those who have benchmarks for innovation, leadership and success.

The “Excellence in Finance – Companies” category celebrates organisations within the finance and fintech sector. Whether you are a pioneering fintech systems, transforming the finance industry, this category recognizes your significant contribution.

The “Excellence in Finance Leaders” category highlights the exceptional individuals within the finance and fintech realm. From CEOs and CFOs to industry influencers, changers and visionaries who have made lasting impact on the industry.

The proprietary services offered by Image Group International include one-on-one coaching sessions, group workshops, and training programs on authentic personal branding.

This service is designed to help and inspire finance industry leaders to set and achieve their goals, overcome obstacles, and make significant “1% changes” in their personal and professional lives. The Wall Street Gravitas™ program offers confidential finance leaders executive coaching to elevate C-suite executives to enhance their communication skills and strategic thinking.

“On behalf of out team I’d like to thank FiNext and all our clients for their trust and support they have given us for 35 years, without them this award would not be possible”, said Jon Michail, Group CEO at Image Group International.

About Image Group International

Authentic Personal & Business Branding› Image Consulting› Reputation Management • One-on-One Coaching • Group Workshops, Seminars, and Events

IGI elevates individuals and businesses to grow and monetize their personal and corporate brands with a holistic approach in order to maximise their business, career, and personal value.

Their clients includes Forbes 100 and AFR 500 rich listers… including large financial institutions such as: Goldman Saches, Commonwealth Bank, ANZ, NAB, Westpac and HSBC.

IGI is recognised as Australasia’s leading personal brand image advisory with extensive experience in APAC- market, China, Hong Kong, Singapore, Malaysia, Indonesia, Thailand, Japan, Korea, and the USA.

About FiNext Awards

The FiNext Awards is a prestigious recognition program that acknowledges companies in the finance and fintech sector. The aim to honour those who have benchmarks for innovation, leadership and success.

With a keen focus on two main categories, “Excellence in Finance – Companies outstanding achievements and noteworthy contributions within the industry gain well-deserved recognition for your hard work and dediction.

Media Contact
Company Name: Image Group International
Contact Person: Patricia Bosa
Email: Send Email
Country: Australia
Website: https://www.imagegroup.com.au/

Nicco Engineering Revolutionizes Industrial Maintenance Sector with Online Leak Sealing and Safety Valve Testing Services

NESL pioneered Online Leak Sealing in India in 1980, and is today the largest leak service company in the country.

California – February 26, 2024 – In today’s fast-paced industrial landscape, maintaining operational efficiency and safety is paramount. Nicco Engineering stands at the forefront of this endeavor, offering cutting-edge solutions in online leak sealing and safety valve testing services.

Nicco Engineering Services Limited

With a commitment to excellence and innovation, Nicco Engineering has redefined industry standards, ensuring seamless operations and enhanced safety across various industrial sectors. Their online leak sealing services are tailored to address leaks in pipes and piping components, flange joints, valve body and valve glands, offering a quick and effective solution without the need for costly shutdowns. This innovative approach minimizes downtime, saving valuable time and resources for their clients.

Furthermore, Nicco Engineering’s safety valve testing and calibration services (Valtest) are designed to ensure the reliability and performance of safety valves, crucial components in maintaining safe operating conditions. Their expert technicians utilize state-of-the-art equipment and adhere to stringent safety standards, providing clients with peace of mind and regulatory compliance.

Nicco Engineering Services Limited

“Nicco Engineering is dedicated to providing our clients with the highest quality services, backed by our expertise and commitment to safety,” says Mr. Amar Chatterjee, Wholetime Director of Nicco Engineering. “We are proud to be leading the way in the industrial maintenance sector, offering innovative solutions that improve efficiency and safety for our clients.”

Nicco also caters to international clients by exporting Leak Sealants and Accessories to more than 22 countries globally. Nicco Online Leak Sealing compounds are now certified by Bureau of Indian Standards (BIS) (Online Leakage Sealing Systems Code of Practice IS 18159:2023).

Nicco Engineering’s online leak sealing and safety valve testing services have garnered praise from clients across various industries, including petrochemicals, power generation, iron and steel, sugar, textiles, pharmaceuticals, and manufacturing. Their reputation for excellence and reliability has made them a trusted partner for companies seeking superior industrial maintenance solutions.

For more information about Nicco Engineering and their services, visit their website at www.niccoengineering.com

About Nicco Engineering Services Limited:

Nicco Engineering is a leading provider of industrial maintenance solutions, specializing in online leak sealing and safety valve testing services. With a focus on innovation and customer satisfaction, Nicco Engineering is dedicated to exceeding industry standards and delivering exceptional results for their clients.

Media Contact
Company Name: Nicco Engineering Services Limited
Contact Person: Amar Chatterjee
Email: Send Email
Phone: +918017021191
Address:Infinium Digispace, 4th Floor, CP-15, Salt Lake City, Sector-V
City: Kolkata 700091
Country: India
Website: https://niccoengineering.com

Jilin City submitted “ice and snow report card”: the number of tourists and tourism revenue double growth

A few days ago, the Jilin municipal government released its official tourism data during the Chinese New Year, the city received a total of 3,668,500 domestic tourists, with its domestic tourism revenue reaching 3.288 billion yuan (approx. $460 million). In the context of the “Northeast ice and snow tourism boom”, the culture and tourism industry has made a good start in the year of the loong (Chinese dragon).

Photo by Han Tao

Jilin City, rich in snow and ice resources, is also one of the representative cities for snow and ice tourism in Northeast China. The local snow fields abound, with two world-class fields, namely Vanke Songhua Lake and Beidahu Lake. The local government plans to build more than ten snow parks in the future, turning the city into one of the world’s top three super ski resorts.

The huge popularity of Northeast cultural tourism boosted the growth of passenger flow in Jilin City. Data show that the Beishan Mountain Scenic Area in the Spring Festival received a total of 1.02 million tourists, an year-on-year increase of 436.84%. The total number of tourists received and the number of tourists received on a single day in Jilin provincial A-level tourist attractions ranked first.

Ski vacation single day reception of tourists also hit a record high since the opening of the business. The cumulative reception of tourists and the revenue of the two snow fields of Beidahu Lake and Vanke Songhua Lake during the Spring Festival increased by 73.7% and 83.6% compared with the same period last year. The two resorts received the highest number of tourists on a single day, that is, 14,900 and 14,200 visitors respectively, both recording the highest number of visitors received in a single day.

Jilin City is reputed as China’s “capital of rime”. This snow season, the frequency of such a natural wonder is the highest in the the last five years. The Small Rime Island in Fengman District set a record of receiving 30,000 visitors in a single day, 80% of whom were non-local tourists.

Photo by Liu Bo

The reporter noticed that the night tour of the city has become a new highlight of this snow season. The local area is based on the unfrozen river with the highest latitude in China, highlighting the Songjiang Middle Road in which a variety of themed activities and new products of culture and tourism have been launched, including the Catholic Church light show, twelve Chinese zodiac snow and ice carvings, the double dragon shows, namely the flying dragon show and the dragon bamboo raft show, and others . Nearly one million visitors were received during the Spring Festival.

Photo by Yang Zijian

In fact, the above good results are attributed to the local government’s initiative to embracing the “flow of people” and to going viral with culture and tourism. In just one week, Songjiang Middle Road has been turned into an “ever-bright street”, and then with the extended opening of the museum and night tour of the Songhua River, the night economy has been full energized.

The craze of culture and tourism also propelled the local commerce and trade. During the Spring Festival, Jilin City saw frequent commercial and trade activities, with sales revenue hitting an all-time best. More than 30 large-scale commercial enterprises carried out over 50 thematic promotional activities. The average daily sales of independently developed cultural and creative products in Jilin City delivered as high as 50,000 yuan (about $7,000), and the sales of 10 special food neighborhoods amounted to 21.6 million yuan ($3 million).

(by Shi Hongyu)

Media Contact
Company Name: Goknews
Contact Person: Bella
Email: Send Email
Country: United States
Website: www.goknews.com